[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-349061-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-349061-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","farnesyltransferase-inhibitor-lb42708-disables-oncogenic-ras-signaling-and-overcomes-gefitinib-resistance-in-nsclc-via-ftase-subunit-and-ras-degradation","Farnesyltransferase inhibitor LB42708 disables oncogenic RAS signaling and overcomes gefitinib resistance in NSCLC via FTase α-subunit and RAS degradation","","RAS mutations represent prevalent oncogenic drivers in human cancers, particularly non-small cell lung cancer (NSCLC). Direct pharmacological targeting of RAS remains challenging because surface RAS lacks druggable binding pockets. LB42708 is a potent, selective farnesyltransferase (FTase) inhibitor that disrupts RAS farnesylation and downstream signaling. It inhibits proliferation, migration, invasion, stemness, and clonal growth of RAS-mutant NSCLC cells, inducing apoptosis and cell-cycle arrest, confirmed in patient-derived organoids and xenografts.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/farnesyltransferase-inhibitor-lb42708-disables-oncogenic-ras-signaling-and-overcomes-gefitinib-resistance-in-nsclc-via-ftase-subunit-and-ras-degradation/349061/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/farnesyltransferase-inhibitor-lb42708-disables-oncogenic-ras-signaling-and-overcomes-gefitinib-resistance-in-nsclc-via-ftase-subunit-and-ras-degradation/349061.png","ImageObject",300,407,{"name":42,"@type":43},"Sarah ","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-13","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",9,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Why is directly targeting RAS with drugs difficult?","Question",{"text":63,"@type":64},"RAS proteins are hard to target because they lack suitable drug-binding pockets on their surfaces.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What is LB42708 and what does it do to RAS signaling?",{"text":68,"@type":64},"LB42708 is a selective farnesyltransferase (FTase) inhibitor that disrupts RAS farnesylation and suppresses downstream signaling.",{"name":70,"@type":61,"acceptedAnswer":71},"How does LB42708 improve outcomes in gefitinib-resistant NSCLC models?",{"text":72,"@type":64},"LB42708 enhances the sensitivity of gefitinib-resistant PC9 cells to gefitinib, and it shows strong anti-tumor effects in combination with AKT inhibition.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},349061,1790147193,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},962085320529,"https://ap-avatar.wpscdn.com/davatar_9964176cb1d06d4a9deccf72a44ae3dc","Luo etal. Cell Communication and Signaling (2026) 24:240  \n[https://doi.org/10.1186/s12964-026-02798-z](https://doi.org/10.1186/s12964-026-02798-z)  \nCell Communication and Signaling  \nRESEARCH Open Access  \nFarnesyltransferase inhibitor LB42708 disables oncogenic RAS signaling and overcomes gefitinib resistance in NSCLC via FTase α-subunit and RAS degradation  \nGuancong Luo1†, Dexuan Li1†, Jun Peng2,3†, Rongsheng Liu2,3†, Yajing Meng4, Richard Ward5, Yangyang Zhang1, Xinyu Zhang3,6, Fengxian Cui2,3, Jiwei Wang1, Xiuyu Yang1, Mo Chen1, Yanjun Xu1, Sheng Chen1, Wenyu Jiang1, Le Zhang1, Yurong Li1, Yang Yang7, Cheng Xiang7, Xiaoxi Guo7, Jiameng Dai7, Jun Sang7, Tian-Rui Xu7,8,9* and Su An7,8,9*  \nAbstract  \nRAS mutations are among the most common oncogenic drivers in human cancers, particularly in non-small  \ncell lung cancer (NSCLC) . Direct targeting of RAS proteins remains difficult due to the lack of suitable drugbinding pockets on their surfaces. LB42708 is a potent and selective farnesyltransferase (FTase) inhibitor that disrupts RAS farnesylation and downstream signaling. This study evaluates the anti-tumor effects of LB42708 in KRAS-and HRAS-mutant NSCLC cells, as well as gefitinib-resistant PC9 (PC9GR) cells. LB42708 significantly inhibits the proliferation, migration, invasion, stemness, and clonal growth of RAS-mutant NSCLC cells, while inducing apoptosis and cell cycle arrest. The inhibitory effects are further validated in patient-derived organoidsand xenograft models. Mechanistically, LB42708 suppresses FTase activity, reduces RAS protein levels through proteasome-dependent degradation, and induces caspase-3–mediated degradation of the shared α-subunit of FTase and geranylgeranyltransferase-1 (GGTase-1) . Combination treatment with LB42708 and the AKT inhibitor AZD5363 (capivasertib) produces synergistic anti-tumor activity in RAS-mutant NSCLC. Moreover, LB42708 enhances the sensitivity of PC9GR cells to gefitinib. Collectively, these findings demonstrate that LB42708, alone or in combination with AZD5363 or gefitinib, represents as a promising therapeutic candidate for NSCLC harboring RAS mutations or resistant to tyrosine kinase inhibitors (TKIs) .  \n†Guancong Luo, Dexuan Li, Jun Peng and Rongsheng Liu contributed equally to this work.  \n*Correspondence: Tian-Rui Xu [tianruixu@kust.edu.cn](tianruixu@kust.edu.cn)[ ](tianruixu@kust.edu.cn)Su An[aslxj@mail.ustc.edu.cn](aslxj@mail.ustc.edu.cn)  \nFull list of author information is available at the end of the article  \n© The Author(s) 2026. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creati](http://creati)[vecommons.org/licenses/by-nc-nd/4.0/](vecommons.org/licenses/by-nc-nd/4.0/.)[.](vecommons.org/licenses/by-nc-nd/4.0/.)  \nLuo et al. Cell Communication and Signaling (2026) 24:240 Page 2 of 25  \nPlain English summary  \nMutations in a family of genes called RAS are among the most common causes of cancer, especially non-small cell lung cancer (NSCLC) . These mutations make cancer cells grow and spread uncontrollably. Unfortunately, RAS proteins are ver","cbCaigaBj90zgljp","https://ap.wps.com/l/cbCaigaBj90zgljp","pdf",16785000,25,"English","# Abstract\n# Plain English summary\n# Introduction","[{\"question\":\"Why is directly targeting RAS with drugs difficult?\",\"answer\":\"RAS proteins are hard to target because they lack suitable drug-binding pockets on their surfaces.\"},{\"question\":\"What is LB42708 and what does it do to RAS signaling?\",\"answer\":\"LB42708 is a selective farnesyltransferase (FTase) inhibitor that disrupts RAS farnesylation and suppresses downstream signaling.\"},{\"question\":\"How does LB42708 improve outcomes in gefitinib-resistant NSCLC models?\",\"answer\":\"LB42708 enhances the sensitivity of gefitinib-resistant PC9 cells to gefitinib, and it shows strong anti-tumor effects in combination with AKT inhibition.\"}]","Farnesyltransferase inhibitor LB42708 disables oncogenic RAS signaling and overcomes gefitinib resistance in NSCLC via FTase α-subunit and RAS degradation | PDF",1790081460,63,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/138206a7ce4626ce7eb689626f4eb917.webp",983,1310,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/cd0010c17c0c954757aa2450aad8b20a.webp",982,1309,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e9bf76afa4eee6e69a4a40c16df9e2e0.webp",981,1308,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8658e4d78b13a91e90627f556041b27e.webp",980,1306]